CMH :: Clinical and Molecular Hepatology

Clinical and Molecular Hepatology Search

> Browse Articles > Search

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

David Sooik Kim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Clin Mol Hepatol.2019;25(3):283-293. Published online November 13, 2018
DOI: https://doi.org/10.3350/cmh.2018.0054

Cited By 1

Unmet need in chronic hepatitis B management

Lilian Yan Liang, Grace Lai-Hung Wong

Clin Mol Hepatol.2019;25(2):172-180. Published online February 12, 2019
DOI: https://doi.org/10.3350/cmh.2018.0106

Cited By 2

KASL clinical practice guidelines for management of chronic hepatitis B

Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol.2019;25(2):93-159. Published online June 12, 2019
DOI: https://doi.org/10.3350/cmh.2019.1002

Cited By 2

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang

Clin Mol Hepatol.2019;25(1):52-64. Published online October 23, 2018
DOI: https://doi.org/10.3350/cmh.2018.0040

Cited By 2

Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B

Hyeji Kim, Jung Hyun Kwon, Yong Hee Kim, Soon Woo Nam, Jong Yul Lee, Jeong Won Jang

Clin Mol Hepatol.2018;24(4):430-435. Published online November 27, 2017
DOI: https://doi.org/10.3350/cmh.2017.0016

Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases

San Juan López Cristina, Casado Martín Marta, González Sánchez Mercedes, Porcel Martín Almudena, Hernández Martínez Álvaro, Vega Sáenz Jose Luis, Parrón Carreño Tesifón

Clin Mol Hepatol.2018;24(4):384-391. Published online July 4, 2018
DOI: https://doi.org/10.3350/cmh.2018.0004

Cited By 2

Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them

Kwang Il Seo, Si Hyun Bae, Pil Soo Sung, Chung-Hwa Park, Hae Lim Lee, Hee Yeon Kim, Hye Ji Kim, Bo Hyun Jang, Jeong Won Jang, Seung Kew Yoon, Jong Young Choi, In-Yang Park, Juyoung Lee, Hyun Seung Lee, Sa-Jin Kim, Jung Hyun Kwon, U Im Chang, Chang Wook Kim, Se Hyun Jo, Young Lee Young Lee, Fisseha Tekle, Jong-Hyun Kim

Clin Mol Hepatol.2018;24(4):374-383. Published online June 26, 2018
DOI: https://doi.org/10.3350/cmh.2017.0082

Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level

Mi Young Jeon, Beom Kyung Kim, Seung Up Kim

Clin Mol Hepatol.2018;24(4):367-369. Published online September 19, 2018
DOI: https://doi.org/10.3350/cmh.2018.1008

Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend

Grace Lai-Hung Wong

Clin Mol Hepatol.2018;24(2):108-113. Published online January 22, 2018
DOI: https://doi.org/10.3350/cmh.2017.0068

Cited By 6

Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B

Kwan Sik Lee, Young-Oh Kweon, Soon-Ho Um, Byung-Ho Kim, Young Suk Lim, Seung Woon Paik, Jeong Heo, Heon-Ju Lee, Dong Joon Kim, Tae Hun Kim, Young-Sok Lee, Kwan Soo Byun, Daeghon Kim, Myung Seok Lee, Kyungha Yu, Dong Jin Suh

Clin Mol Hepatol.2017;23(4):331-339. Published online September 26, 2017
DOI: https://doi.org/10.3350/cmh.2016.0040

Cited By 2

Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?

Joon Yeul Nam, Jeong-Hoon Lee

Clin Mol Hepatol.2017;23(4):311-313. Published online December 4, 2017
DOI: https://doi.org/10.3350/cmh.2017.0069

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir

Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin

Clin Mol Hepatol.2017;23(3):230-238. Published online June 30, 2017
DOI: https://doi.org/10.3350/cmh.2017.0003

Cited By 4

Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?

Yun Bin Lee, Jeong-Hoon Lee

Clin Mol Hepatol.2017;23(3):219-221. Published online September 19, 2017
DOI: https://doi.org/10.3350/cmh.2017.0045

Current status and strategies for hepatitis B control in Korea

Eun Ju Cho, Sung Eun Kim, Ki Tae Suk, Jihyun An, Soung Won Jeong, Woo Jin Chung, Yoon Jun Kim

Clin Mol Hepatol.2017;23(3):205-211. Published online September 19, 2017
DOI: https://doi.org/10.3350/cmh.2017.0104

Cited By 22

Current status and strategies for viral hepatitis control in Korea

Dong Hyun Sinn, Eun Ju Cho, Ji Hoon Kim, Do Young Kim, Yoon Jun Kim, Moon Seok Choi

Clin Mol Hepatol.2017;23(3):189-195. Published online September 19, 2017
DOI: https://doi.org/10.3350/cmh.2017.0033

Cited By 5

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B

Won Sohn, Ju-Yeon Cho, Ji Hoon Kim, Jung Il Lee, Hyung Joon Kim, Min-Ah Woo, Sin-Ho Jung, Yong-Han Paik

Clin Mol Hepatol.2017;23(2):170-178. Published online May 16, 2017
DOI: https://doi.org/10.3350/cmh.2016.0086

Cited By 6

Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B

Hee Yeon Seo, Han Ah Lee, Soon Young Ko, Joon Ho Wang, Jeong Han Kim, Won Hyeok Choe, So Young Kwon

Clin Mol Hepatol.2017;23(2):154-159. Published online May 8, 2017
DOI: https://doi.org/10.3350/cmh.2016.0067

Cited By 2

Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis

Oidov Baatarkhuu, Hye Won Lee, Jacob George, Dashchirev Munkh-Orshikh, Baasankhuu Enkhtuvshin, Sosorbaram Ariunaa, Mohammed Eslam, Sang Hoon Ahn, Kwang-Hyub Han, Do Young Kim

Clin Mol Hepatol.2017;23(2):147-153. Published online May 2, 2017
DOI: https://doi.org/10.3350/cmh.2016.0055

Cited By 3

Meta-analysis of the correlation between the rs17401966 polymorphism in kinesin family member 1B and susceptibility to hepatitis B virus related hepatocellular carcinoma

Mingkuan Su, Jianfeng Guo, Jiancheng Huang

Clin Mol Hepatol.2017;23(2):138-146. Published online April 21, 2017
DOI: https://doi.org/10.3350/cmh.2016.0083

Cited By 2

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?

Nae-Yun Heo

Clin Mol Hepatol.2017;23(2):125-127. Published online June 23, 2017
DOI: https://doi.org/10.3350/cmh.2017.0106

Cited By 1

Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients

Goh Eun Chung, Eun Ju Cho, Jeong-Hoon Lee, Jeong-ju Yoo, Minjong Lee, Yuri Cho, Dong Hyeon Lee, Hwi Young Kim, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim

Clin Mol Hepatol.2017;23(1):66-73. Published online February 14, 2017
DOI: https://doi.org/10.3350/cmh.2016.0060

Cited By 6

Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization

Sun Hong Yoo, Jeong Won Jang, Jung Hyun Kwon, Seung Min Jung, Bohyun Jang, Jong Young Choi

Clin Mol Hepatol.2016;22(4):458-465. Published online December 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0054

Cited By 2

Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)

Hye Won Lee, Jun Yong Park, Beom Kyung Kim, Moon Young Kim, Jung Il Lee, Young Suk Kim, Ki Tae Yoon, Kwang-Hyub Han, Sang Hoon Ahn

Clin Mol Hepatol.2016;22(4):443-449. Published online November 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0037

Cited By 5

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?

Byung-Cheol Song

Clin Mol Hepatol.2016;22(4):439-442. Published online December 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0108

New perspectives of biomarkers for the management of chronic hepatitis B

Chih-Lin Lin, Jia-Horng Kao

Clin Mol Hepatol.2016;22(4):423-431. Published online December 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0069

Cited By 25

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B

Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um

Clin Mol Hepatol.2016;22(3):382-389. Published online September 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0047

Cited By 4

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment

Hong Joo Kim, Soo Kyung Park, Hyo Joon Yang, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Yong Choi

Clin Mol Hepatol.2016;22(3):350-358. Published online September 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0019

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B

Jaemin Lee, Sun Hong Yoo, Won Sohn, Hyung Woo Kim, Yong Sun Choi, Jung Ho Won, Jin Young Heo, Sang Jong Park, Young Min Park

Clin Mol Hepatol.2016;22(3):339-349. Published online September 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0021

Cited By 3

Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients?

Byoung Kuk Jang

Clin Mol Hepatol.2016;22(3):336-338. Published online September 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0104

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy

Ioannis Varbobitis, George V. Papatheodoridis

Clin Mol Hepatol.2016;22(3):319-326. Published online September 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0045

Cited By 24

1 | 2 | 3 | 4 | 5 | 6 | 7 |

The Korean Association for the Study of the Liver